Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 112

1.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K.

Ann Surg Oncol. 2016 Feb 8. [Epub ahead of print]

PMID:
26856721
2.

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review).

Andergassen U, Kölbl AC, Mahner S, Jeschke U.

Oncol Rep. 2016 Feb 2. doi: 10.3892/or.2016.4608. [Epub ahead of print]

PMID:
26848098
3.

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.

Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S.

Br J Cancer. 2016 Jan 19;114(2):207-12. doi: 10.1038/bjc.2015.436.

PMID:
26757261
4.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2015 Dec 28. pii: S0090-8258(15)30229-8. doi: 10.1016/j.ygyno.2015.12.025. [Epub ahead of print]

PMID:
26731724
5.

Partial PTEN deletion is linked to poor prognosis in breast cancer.

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von D Assen A, Müller V, Burandt E.

BMC Cancer. 2015 Dec 16;15(1):963. doi: 10.1186/s12885-015-1770-3.

6.

Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function.

VON Bülow C, Oliveira-Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K.

Mol Clin Oncol. 2015 Sep;3(5):1067-1072. Epub 2015 Jul 1.

7.

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.

Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A.

Int J Gynecol Cancer. 2015 Nov 19. [Epub ahead of print]

PMID:
26588236
8.

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.

Mahner S, Woelber L, Mueller V, Witzel I, Prieske K, Grimm D, Keller-V Amsberg G, Trillsch F.

Front Oncol. 2015 Oct 5;5:211. doi: 10.3389/fonc.2015.00211. eCollection 2015. Review.

9.

Fetal gender specific expression of tandem-repeat galectins in placental tissue from normally progressed human pregnancies and intrauterine growth restriction (IUGR).

Hutter S, Knabl J, Andergassen U, Mayr D, Hofmann S, Kuhn C, Mahner S, Arck P, Jeschke U.

Placenta. 2015 Dec;36(12):1352-61. doi: 10.1016/j.placenta.2015.09.015. Epub 2015 Oct 3.

PMID:
26462906
10.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2015 Sep 29. [Epub ahead of print]

PMID:
26419591
11.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H.

Br J Cancer. 2015 Nov 3;113(9):1358-66. doi: 10.1038/bjc.2015.340. Epub 2015 Sep 22.

PMID:
26393886
12.

Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment.

Grimm D, Hasenburg A, Eulenburg C, Steinsiek L, Mayer S, Eltrop S, Prieske K, Trillsch F, Mahner S, Woelber L.

Int J Gynecol Cancer. 2015 Jul;25(6):1134-41. doi: 10.1097/IGC.0000000000000468.

PMID:
26098093
13.

Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions.

Grimm D, Eulenburg C, Brummer O, Schliedermann AK, Trillsch F, Prieske K, Gieseking F, Selka E, Mahner S, Woelber L.

Support Care Cancer. 2016 Jan;24(1):419-28. doi: 10.1007/s00520-015-2812-8. Epub 2015 Jun 23.

PMID:
26094599
14.

Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.

Oliveira-Ferrer L, Heßling A, Trillsch F, Mahner S, Milde-Langosch K.

Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.

PMID:
26084610
15.

Systemic treatment of vulvar cancer.

Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L.

Expert Rev Anticancer Ther. 2015 Jun;15(6):629-37. doi: 10.1586/14737140.2015.1037837. Epub 2015 May 21. Review.

PMID:
25997120
16.

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.

Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators.

Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476.

PMID:
25978292
17.

8p deletion is strongly linked to poor prognosis in breast cancer.

Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E.

Cancer Biol Ther. 2015;16(7):1080-7. doi: 10.1080/15384047.2015.1046025. Epub 2015 May 11.

PMID:
25961141
18.

A systematic model specification procedure for an illness-death model without recovery.

Eulenburg C, Mahner S, Woelber L, Wegscheider K.

PLoS One. 2015 Apr 13;10(4):e0123489. doi: 10.1371/journal.pone.0123489. eCollection 2015.

19.

Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J.

Eur J Cancer. 2015 May;51(7):825-32. doi: 10.1016/j.ejca.2015.01.008. Epub 2015 Mar 11.

PMID:
25771433
20.

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L; AGO-CaRE 1 investigators.

J Natl Cancer Inst. 2015 Jan 24;107(3). pii: dju426. doi: 10.1093/jnci/dju426. Print 2015 Mar.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk